125 related articles for article (PubMed ID: 12642691)
1. The histone deacetylase inhibitor FR901228 (desipeptide) restores expression and function of pseudo-null p53.
Kitazono M; Bates S; Fok P; Fojo T; Blagosklonny MV
Cancer Biol Ther; 2002; 1(6):665-8. PubMed ID: 12642691
[TBL] [Abstract][Full Text] [Related]
2. P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228.
Sandor V; Senderowicz A; Mertins S; Sackett D; Sausville E; Blagosklonny MV; Bates SE
Br J Cancer; 2000 Sep; 83(6):817-25. PubMed ID: 10952788
[TBL] [Abstract][Full Text] [Related]
3. Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors.
Blagosklonny MV; Trostel S; Kayastha G; Demidenko ZN; Vassilev LT; Romanova LY; Bates S; Fojo T
Cancer Res; 2005 Aug; 65(16):7386-92. PubMed ID: 16103091
[TBL] [Abstract][Full Text] [Related]
4. FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells.
Sato N; Ohta T; Kitagawa H; Kayahara M; Ninomiya I; Fushida S; Fujimura T; Nishimura G; Shimizu K; Miwa K
Int J Oncol; 2004 Mar; 24(3):679-85. PubMed ID: 14767553
[TBL] [Abstract][Full Text] [Related]
5. Antiproliferative effects of the histone deacetylase inhibitor FR901228 on small-cell lung cancer lines and drug-resistant sublines.
Tsurutani J; Soda H; Oka M; Suenaga M; Doi S; Nakamura Y; Nakatomi K; Shiozawa K; Amada YY; Kamihira S; Kohno S
Int J Cancer; 2003 Mar; 104(2):238-42. PubMed ID: 12569581
[TBL] [Abstract][Full Text] [Related]
6. Depsipeptide (FR901228) inhibits proliferation and induces apoptosis in primary and metastatic human uveal melanoma cell lines.
Klisovic DD; Katz SE; Effron D; Klisovic MI; Wickham J; Parthun MR; Guimond M; Marcucci G
Invest Ophthalmol Vis Sci; 2003 Jun; 44(6):2390-8. PubMed ID: 12766035
[TBL] [Abstract][Full Text] [Related]
7. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228.
Yu X; Guo ZS; Marcu MG; Neckers L; Nguyen DM; Chen GA; Schrump DS
J Natl Cancer Inst; 2002 Apr; 94(7):504-13. PubMed ID: 11929951
[TBL] [Abstract][Full Text] [Related]
8. Effects of FK228, a novel histone deacetylase inhibitor, on tumor growth and expression of p21 and c-myc genes in vivo.
Sasakawa Y; Naoe Y; Inoue T; Sasakawa T; Matsuo M; Manda T; Mutoh S
Cancer Lett; 2003 Jun; 195(2):161-8. PubMed ID: 12767524
[TBL] [Abstract][Full Text] [Related]
9. Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells.
Kitazono M; Robey R; Zhan Z; Sarlis NJ; Skarulis MC; Aikou T; Bates S; Fojo T
J Clin Endocrinol Metab; 2001 Jul; 86(7):3430-5. PubMed ID: 11443220
[TBL] [Abstract][Full Text] [Related]
10. Enhanced transgene expression in urothelial cancer gene therapy with histone deacetylase inhibitor.
Okegawa T; Nutahara K; Pong RC; Higashihara E; Hsieh JT
J Urol; 2005 Aug; 174(2):747-52. PubMed ID: 16006969
[TBL] [Abstract][Full Text] [Related]
11. Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents.
Mujoo K; Watanabe M; Nakamura J; Khokhar AR; Siddik ZH
J Cancer Res Clin Oncol; 2003 Dec; 129(12):709-18. PubMed ID: 14513366
[TBL] [Abstract][Full Text] [Related]
12. Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1).
Zhao Y; Lu S; Wu L; Chai G; Wang H; Chen Y; Sun J; Yu Y; Zhou W; Zheng Q; Wu M; Otterson GA; Zhu WG
Mol Cell Biol; 2006 Apr; 26(7):2782-90. PubMed ID: 16537920
[TBL] [Abstract][Full Text] [Related]
13. Changes in cyclins and cyclin-dependent kinases induced by DNA damaging agents in a human ovarian cancer cell line expressing mutated or wild-type P53.
Vikhanskaya F; Erba E; D'Incalci M; Broggini M
Exp Cell Res; 1996 Sep; 227(2):380-5. PubMed ID: 8831577
[TBL] [Abstract][Full Text] [Related]
14. Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop.
Arriola EL; Lopez AR; Chresta CM
Oncogene; 1999 Jan; 18(4):1081-91. PubMed ID: 10023685
[TBL] [Abstract][Full Text] [Related]
15. Mdm2 inhibition of p53 induces E2F1 transactivation via p21.
Wunderlich M; Berberich SJ
Oncogene; 2002 Jun; 21(28):4414-21. PubMed ID: 12080472
[TBL] [Abstract][Full Text] [Related]
16. DNA damage-induced phosphorylation of p53 at serine 20 correlates with p21 and Mdm-2 induction in vivo.
Jabbur JR; Huang P; Zhang W
Oncogene; 2000 Dec; 19(54):6203-8. PubMed ID: 11175334
[TBL] [Abstract][Full Text] [Related]
17. Role of MDM2 overexpression in doxorubicin resistance of breast carcinoma.
Suzuki A; Toi M; Yamamoto Y; Saji S; Muta M; Tominaga T
Jpn J Cancer Res; 1998 Feb; 89(2):221-7. PubMed ID: 9548451
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation of serines 15 and 37 is necessary for efficient accumulation of p53 following irradiation with UV.
Bean LJ; Stark GR
Oncogene; 2001 Mar; 20(9):1076-84. PubMed ID: 11314044
[TBL] [Abstract][Full Text] [Related]
19. Differences in mutant p53 protein stability and functional activity in teniposide-sensitive and -resistant human leukemic CEM cells.
Morgan SE; Kim R; Wang PC; Bhat UG; Kusumoto H; Lu T; Beck WT
Oncogene; 2000 Oct; 19(43):5010-9. PubMed ID: 11042688
[TBL] [Abstract][Full Text] [Related]
20. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor.
Nakajima H; Kim YB; Terano H; Yoshida M; Horinouchi S
Exp Cell Res; 1998 May; 241(1):126-33. PubMed ID: 9633520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
